Frossard JL, Morel P, Kwak B, Pastor C, Berney T, Buhler L, Von Laufen A, Demulder S, Mach F. Soluble CD40 ligand in prediction of acute severe pancreatitis. World J Gastroenterol 2006; 12(10): 1613-1616
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Soluble CD40 ligand in prediction of acute severe pancreatitis
Jean Louis Frossard, Philippe Morel, Brenda Kwak, Catherine Pastor, Thierry Berney, Léo Buhler, Alain Von Laufen, Sandrine Demulder, Francois Mach
Jean Louis Frossard, Catherine Pastor, Alain Von Laufen, Division of Gastroenterology, Geneva University Hospital, Genève, Switzerland
Philippe Morel, Thierry Berney, Sandrine Demulde, Clinic of Digestive Surgery, Geneva University Hospital, Genève, Switzerland
Brenda Kwak, François Mach, Division of Cardiology, Geneva University Hospital, Genève, Switzerland
ORCID number: $[AuthorORCIDs]
Author contributions: All authors contributed equally to the work.
Supported by a grant from the Fonds de Pérequation des Hôpitaux Universitaires de Genève (to JLF) and Fondation Schmiedheiny
Correspondence to: JL Frossard, MD, Division de gastroentérologie, Hôpital cantonal universitaire,1211 Genève 14, Switzerland. email@example.com
Telephone: +41-022-3729340 Fax: +41-022-3729366
Received: August 8, 2005 Revised: August 14, 2005 Accepted: August 26, 2005 Published online: March 14, 2006
AIM: To assess the early predictability of the soluble CD40L (sCD40L) in pancreatitis severity.
METHODS: Between February 2000 and February 2003, 279 consecutive patients with acute pancreatitis were prospectively enrolled in our study. In this report, 40 patients with mild and 40 patients with severe pancreatitis were randomly studied. sCD40L concentrations were measured 48 hours after admission.
RESULTS: sCD40L levels were significantly higher 48 hours after admission in severe pancreatitis than in mild pancreatitis. Using a cutoff of 1 000 pg/L, the sensitivity and specificity of sCD40L to detect a severe course of the disease were 78% and 62% respectively compared to 72% and 81% for CRP. Logistic regression analysis found that CRP was the only statistically significant marker able to detect a severe course of the disease.
CONCLUSION: These findings indicate that CRP remains a valuable marker to determine the severity and prognosis of acute pancreatitis whereas sCD40L levels should be assessed in further studies.
Citation: Frossard JL, Morel P, Kwak B, Pastor C, Berney T, Buhler L, Von Laufen A, Demulder S, Mach F. Soluble CD40 ligand in prediction of acute severe pancreatitis. World J Gastroenterol 2006; 12(10): 1613-1616
Acute pancreatitis (AP) is a disease of variable severity. While approximately 80% of patients experience mild attacks, the remaining 20% still suffer from severe disease, with a mortality rate as high as 30%[1,2]. Since treatment of patients with severe disease is currently mostly supportive and directs at either prevention or control of the local and systemic complications, the early prediction of the severity of AP is the main goal of clinicians in charge of such patients. Multifactorial scales including Ranson and APACHE II scoring systems have been used in acute pancreatitis since the 1980s. Ranson scale has been used in the 1980s in virtually all studies dealing with acute pancreatitis[3,4]. The list of 11 numerical parameters proposed by Ranson has no been fully discussed because only 5 criteria are obtained at admission and the remaining 6 during the subsequent 48 hour period, delay the performance of an early prediction. Moreover, the complexity of these scales and perhaps the fact that CT scanners are not available in every hospital account for the increasing interest in serum markers.
The pathophysiology of acute pancreatitis includes the activation and release of pancreatic enzymes in the interstitium, pancreatic autodigestion, and a multiple organ dysfunction following the release of these enzymes into the systemic circulation[6,7]. There is evidence that synthesis and release of pro-inflammatory cytokines and chemokines are also responsible for local and distant injuries[8,9]. If the concentration of these biological factors is correlated to the severity of the disease and if they are detected before the occurrence of multiple organ dysfunction, these factors might be important for the rapid scoring of the disease severity in the acute phase.
CD40, a proteic member of the tumour necrosis factor receptor family, is expressed on the membrane of a variety of cells, including B lymphocytes, monocytes, biliary and acinar cells as recently shown by our group[7,10]. CD40 binds to its ligand CD40L, a membrane glycoprotein, to mediate major immunoregulatory signals involved in auto-immune disease, graft rejection, inflammatory bowel disease, development of atherosclerosis and acute experimental pancreatitis. We postulated that CD40-CD40L interactions might also play a role in the pathogenesis of human pancreatitis and that the soluble form of CD40L (sCD40L) levels might be correlated to the severity of the disease. The purpose of this study was to assess the early predictability of sCD40L in pancreatitis severity.
MATERIALS AND METHODS
The study protocol was approved by the local Ethics Committee. Upon admission, all patients with acute pancreatitis meeting the criteria of inclusion were identified and proposed to be included in the study. Before inclusion, each patient gave an informed consent. Between February 2000 and February 2003, 279 consecutive patients with acute pancreatitis were prospectively enrolled in our study. We assessed the role of sCD40L in the prediction of the severity of pancreatitis in this preliminary study. Consequently, 40 patients with mild and 40 patients with severe pancreatitis were randomly evaluated in the current study (Table 1). Ten healthy controls from our own divisions were also used for comparison. Inclusion criteria were typical abdominal pain associated with serum amylase twice the upper limit value (range: 26-128 U/L). The diagnosis was subsequently confirmed by CT scan with a Picker 1200 or a PQ-2000 instrument. Before scanning 150 ml of diluted oral contrast material (Telebrix Gastro, France) was administered to visualize the gastrointestinal tract. Intravenous contrast material (Omnipaque 350, Shering, Germany) was injected and multiple scans were obtained from the pancreas to the pelvis as previously described. Pancreatic necrosis was considered significant if there was > 30% necrosis of the gland. Pancreatitis severity was defined according to the Atlanta classification and included organ failure (e.g.,shock, pulmonary insufficiency, renal failure), the presence of local complications (pancreatic necrosis, pseudocysts, abscess), or both. Blood samples drawn 48 hours after admission were used to measure CRP and sCD40L using commercially available kits (Behring, Marburg, Germany and Bender MedSystems Vienna, Austria).
Serum markers were compared during severe and mild attacks by univariate analysis (Student’t-test, Mann-Whitney). SCD40L, CRP and Ranson scores were evaluated by receiver operating characteristics (ROC) curves for selected sCD40L and historically determined (CRP and Ranson) cutoff levels[3,4,5]. The cutoff for CRP (150 mg/L) and Ranson (severe > 3) was chosen according to the literature[4,5]. The cutoff for sCD40L was chosen according to its ROC curve. A logistic regression analysis for the binary outcome of mild or severe pancreatitis was performed. P < 0.05 was considered statistically significant. Statistics calculations were done using SPSS Software package (Chicago, USA).
The delay between the onset of abdominal pain and admission ranged from 7 hours to 2 d (Table 1). The aetiology of acute pancreatitis was biliary in 38 patients (48%), alcoholism in 30 (38%), drug-induced pancreatitis in 2 (3 %), hypertriglyceridemia in 1 (2 %) and idiopathic in the remaining 9 patients (11%) (Table1).
CT scan was obtained within 36 hours after admission in each patient and showed a normal pancreas in 5 patients, edema in 47 patients and necrosis in 28 patients (Table 1). Acute fluid collections were found in 35 patients (43 %) (Table1). The Ranson score established at 48 hours was ≥ 3 in 27 patients (33 %), 19 of whom had severe pancreatitis and 8 mild pancreatitis. Sensitivity, specificity, positive predictive value, and negative predictive value of Ranson score to predict a severe attack were 48% and 80%, and 70% and 60% respectively (Table 2). Three patients group with severe pancreatitis (7.5 %) died, two of whom were of biliary origin (Table 1).
Table 2 Performances of sCD40L, CRP and RANSON score.
sCD40L (cutoff 1 000 pg/L)
CRP (150 mg/L)
RANSON Score (>3)
Healthy controls had very low levels of sCD40L as well as CRP (Table 1). By comparison, levels of sCD40L and CRP were 795 pg/L (CI 95 %: 692-1301) and 42.5 mg/L (CI95%: 50-101) in patients with mild pancreatitis and 1215 pg/L (C I95% 1186-1753) and 225 mg/L (CI 95 % 199-319) (P <0.0007 and P <0.0001) in patients with severe pancreatitis respectively (Table 1 and Figure 1). No significant correlation was found between serum levels of sCD40L and the nature of the complications that occurred in patients with severe pancreatitis. There was only a trend towards correlation between sCD40L and the occurrence of multiple organ failure. The three patients who died from severe pancreatitis had intermediate levels of sCD40L (range from 184 to 236 pg/L). The sensitivity, specificity, positive predictive value, and negative predictive value of CRP to predict a severe attack were 72% and 81% respectively and 80% and 74% respectively (Table 2). Ranson score, CRP and sCD40L results were evaluated by their ROC curves for selected cutoff levels (Figure 1). Using a cutoff of 1000 pg/L for sCD40L as defined by the ROC curve, the sensitivity, specificity, positive predictive value and negative predictive value of sCD40L to predict a severe attack were 77% and 62% respectively, whereas the positive and negative predictive values were 63 % and 74% (Table 2). Logistic regression analysis for the binary outcome of mild or severe pancreatitis was performed to better delineate the performance of Ranson score, CRP and sCD40L (Figure 2). The forward stepwise analysis found that CRP at d 2 was the only statistically significant parameter to predict a severe disease (P < 0.001).
Figure 1 Soluble CD40L concentrations in healthy controls, severe and mild pancreatitis patients.
Horizontal bars delineate the mean value.
Figure 2 sCD40L (400, 800, 1 000, 1 200 1 400 and 2 000 pg/L), CRP (50, 150 and 200 mg/L) and Ranson (Ranson score of 2, 3 and 4) ROC curves with selected or historically determined cutoffs in patients with mild and severe pancreatitis.
Predicting the course of acute pancreatitis remains a challenge for the physician. Moreover, the 48-hour delay necessary to collect the standard scores and the complexity of multifactorial scales have prompted many physicians to investigate new markers. CRP is an acute phase protein produced by the liver during inflammatory conditions that was first described in 1930. In the mid-1980s, several studies showed that CRP could be considered as a valuable prognostic factor for severe pancreatitis[3,5,14]. Indeed, a better understanding of the pathophysiology of acute pancreatitis may contribute to a better selection of a specific prognostic marker. To this end, CD40-CD40L interaction, a major pro-inflammatory system widely distributed on a variety of leukocytes, has been recently studied in experimental rodent pancreatitis. The expression of CD40 and its ligand were detected on pancreatic acinar cell surface, and peripheral T lymphocytes showed a progressive increase in the expression of CD40L during the course of experimental pancreatitis. Taken together, we thought that these findings might be applied to human pancreatitis. In the current report where 40 patients with mild and 40 patients with severe pancreatitis were randomly evaluated, we showed for the first time that the levels of the soluble form of CD40L (sCD40L) were higher in severe than in mild pancreatitis 48 hours after admission. The usefulness of this potential new marker has been compared to CRP, the most widely accepted serum marker that is used on a daily routine in almost all hospitals[3,7] and to Ranson score. We found that the sensitivity of sCD40L to predict a severe course was better than that by CRP. The negative predictive value of sCD40L that allows the physician to really exclude a severe disease was superior than that by CRP. A marker characterized by a better negative predictive allows cost savings since it can avoid useless observation time in emergency room or intensive care unit[15,16]. However, logistic regression analysis found that CRP was the only statistically significant marker able to identify a patient who developed a severe course of the disease. One explanation for this result is that our study was limited by the small number of patients evaluated. Consequently, correlation between the levels of sCD40L and the occurrence of complications or death for example could not be studied.
Of note, Ranson score appeared insufficiently predictive of severe attacks, a feature already reported in several previous prospective studies[14,17,18]. To predict the severity of pancreatic disease itself, before the occurrence of multiple organ dysfunction, numerous other factors besides CRP have been evaluated so far with various performances. These factors are either enzymes released from the pancreas such as trypsinogen activation peptide or mediators induced by inflammation in the pancreas itself or in remote organs such as procalcitonin, adhesion molecules or cytokines. For most of them, the higher the blood concentrations of these enzymes or mediators are, the more severe the disease is. Soluble CD40L could be one of the next markers of pancreatitis severity but further larger studies are needed to validate its clinical use in the early assessment of pancreatitis severity.
S- Editor Guo SY L- Editor Zhang JZ E- Editor Liu WF
Tikhonova EP. [Elimination of the instability of blood glucose level as a measure of increasing the effectiveness of insulin therapy in insulin-dependent diabetes mellitus].Ter Arkh. 1989;61:81-84.
Williamson RC. Early assessment of severity in acute pancreatitis.Gut. 1984;25:1331-1339.
Ranson JH, Pasternack BS. Statistical methods for quantifying the severity of clinical acute pancreatitis.J Surg Res. 1977;22:79-91.
Wilson C, Heath DI, Imrie CW. Prediction of outcome in acute pancreatitis: a comparative study of APACHE II, clinical assessment and multiple factor scoring systems.Br J Surg. 1990;77:1260-1264.
Frossard JL, Hadengue A, Pastor CM. New serum markers for the detection of severe acute pancreatitis in humans.Am J Respir Crit Care Med. 2001;164:162-170.
Frossard JL. Trypsin activation peptide (TAP) in acute pancreatitis: from pathophysiology to clinical usefulness.JOP. 2001;2:69-77.
Frossard JL, Kwak B, Chanson M, Morel P, Hadengue A, Mach F. Cd40 ligand-deficient mice are protected against cerulein-induced acute pancreatitis and pancreatitis-associated lung injury.Gastroenterology. 2001;121:184-194.
Frossard JL, Saluja A, Bhagat L, Lee HS, Bhatia M, Hofbauer B, Steer ML. The role of intercellular adhesion molecule 1 and neutrophils in acute pancreatitis and pancreatitis-associated lung injury.Gastroenterology. 1999;116:694-701.
Pastor CM, Matthay MA, Frossard JL. Pancreatitis-associated acute lung injury: new insights.Chest. 2003;124:2341-2351.
Mach F, Schonbeck U, Libby P. CD40 signaling in vascular cells: a key role in atherosclerosis.Atherosclerosis. 1998;137 Suppl:S89-S95.
Robert JH, Frossard JL, Mermillod B, Soravia C, Mensi N, Roth M, Rohner A, Hadengue A, Morel P. Early prediction of acute pancreatitis: prospective study comparing computed tomography scans, Ranson, Glascow, Acute Physiology and Chronic Health Evaluation II scores, and various serum markers.World J Surg. 2002;26:612-619.
Bradley EL. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992.Arch Surg. 1993;128:586-590.
Puolakkainen P, Valtonen V, Paananen A, Schröder T. C-reactive protein (CRP) and serum phospholipase A2 in the assessment of the severity of acute pancreatitis.Gut. 1987;28:764-771.
Herouy Y, Hellstern MO, Vanscheidt W, Schopf E, Norgauer J. Factor XIII-mediated inhibition of fibrinolysis and venous leg ulcers.Lancet. 2000;355:1970-1971.
Frossard JL, Robert J, Soravia C, Mensi N, Magnin A, Hadengue A, Rohner A, Morel P. Early prediction in acute pancreatitis: the contribution of amylase and lipase levels in peritoneal fluid.JOP. 2000;1:36-45.
Ranson JH, Rifkind KM, Turner JW. Prognostic signs and nonoperative peritoneal lavage in acute pancreatitis.Surg Gynecol Obstet. 1976;143:209-219.
Rau B, Steinbach G, Gansauge F, Mayer JM, Grünert A, Beger HG. The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis.Gut. 1997;41:832-840.
Kaufmann P, Tilz GP, Smolle KH, Demel U, Krejs GJ. Increased plasma concentrations of circulating intercellular adhesion molecule-1 (cICAM-1) in patients with necrotizing pancreatitis.Immunobiology. 1996;195:209-219.
Frossard JL. Pathophysiology of acute pancreatitis: a multistep disease.Acta Gastroenterol Belg. 2003;66:166-173.